On October 30, 2015 Adaptimmune Therapeutics plc (Nasdaq: ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, reported that it will present new data from trials of its NY-ESO affinity enhanced T-cell therapy in patients with synovial sarcoma and myeloma, as well as data from preclinical safety assessments of its affinity enhanced T-cell therapy directed at MAGE A-10, at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC) (Free SITC Whitepaper) (Press release, Adaptimmune, OCT 30, 2015, View Source [SID:1234507856]). SITC (Free SITC Whitepaper) is the world’s leading member-driven organization specifically dedicated to professionals working in the field of cancer immunology and immunotherapy. The meeting will take place at the McCormick Place exhibition center in National Harbor, MD on November 4 through 8, 2015.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Adaptimmune’s poster presentations will take place on November 6, 2015 in the Prince George’s Exhibition Hall from 12:45 to 2:00 pm and are as follows:
Friday November 6, 2015
Poster Presentations
Presentation Time: 12:45-2:00 pm
Location: Prince George’s Exhibition Hall
Track Name: Clinical Trials in Progress
Abstract number: 112286
Title: "Optimizing engineered TCR T-cell therapy for synovial sarcoma"
Sandra D’Angelo, M.D., Assistant Attending, Sarcoma Medical Oncology / Immunotherapeutics Core at Memorial Sloan-Kettering Cancer Center will provide additional data from the Company’s NY-ESO-1 synovial sarcoma study. Updates will include data on the expanded study group, longer follow-up and time-to-event, as well as updated correlative and safety data, and characterization of the product pre and post infusion.
Track Name: Mechanisms and Responses to Immune Therapy
Abstract number: 112346
Title: "Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma"
Presenter: Eduardo Davila, Ph.D., Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine, Program Leader for Tumor Immunology and Immunotherapy Research Program at the Greenebaum Cancer Center at the University of Maryland will present follow-up data from the recently published Nature Medicine paper, including details on NY-ESO-1 T-cell phenotyping and functional data, as well as clinical and basic correlative data in myeloma patients.
Track Name: Adoptive Immunotherapy
Abstract number: 112244
Title: "Preclinical safety testing of an affinity-optimized MAGE-A10 T cell receptor for adoptive T cell therapy"
Presenter: Andrew Gerry, Ph.D., Director of Preclinical Research, Adaptimmune Therapeutics will provide a summary of the preclinical safety testing of the Company’s next affinity optimized TCR entering clinical studies in 2015, an affinity-enhanced T-cell therapy targeting MAGE-A10 in patients with non-small cell lung cancer.
Adaptimmune’s affinity enhanced T-cell candidates are novel cancer immunotherapies that have been engineered to target and destroy cancer cells by strengthening a patient’s natural T-cell response. T-cells are a type of white blood cell that play a central role in a person’s immune response. Adaptimmune’s goal is to harness the power of the T-cell and, through its multiple therapeutic candidate, significantly impact cancer treatment and clinical outcomes of patients with multiple solid and hematologic cancers.